Efficacy and Safety of Stannsoporfin in Neonates

A Multicenter Study to Evaluate the Efficacy and Safety of Tin Mesoporphyrin (Stannsoporfin) to Reduce the Need for Phototherapy in Term and Near Term Infants.


Lead Sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

Source Mallinckrodt
Brief Summary

This is a multi-center, randomized, sham injection-controlled (placebo) masked trial of a single intramuscular injection of Stannsoporfin compared to "sham" (placebo) in healthy term and near-term newborns admitted to the well-baby nursery and enrolled with "intention to treat".

Detailed Description

For purposes of analysis, 2 patient populations are defined. One population consists of those babies who did not develop severe hyperbilirubinemia (TSB <9 mg/dL) during the first 36 hours of age. This population is referred to as the untreated population of screened but not randomized patients. The second population of babies was defined as those infants who develop severe hyperbilirubinemia. These infants were randomized to treatment with either stannsoporfin or the sham injection and will be the focus of the efficacy and safety analysis. This population was referred to as the treated population. The treated population was used for the efficacy and safety analysis. These infants were randomized to either stannsoporfin or the sham injection treatment group.

Overall Status Completed
Start Date 2002-05-01
Completion Date 2013-02-01
Primary Completion Date 2003-03-16
Phase Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Need for Phototherapy 30 days
Secondary Outcome
Measure Time Frame
hyperbilirubinemia 12 hrs
Enrollment 185

Intervention Type: Drug

Intervention Name: stannsoporfin

Description: Intramuscular injection of stannsoporfin to treat jaundice.

Arm Group Label: Active drug-Stannsoporfin

Intervention Type: Other

Intervention Name: Sham Injection

Description: nothing

Arm Group Label: Reference Therapy-Sham



Patients were enrolled who meet the following criteria: 1. The infant's family may be approached at anytime from 6 hours after birth onward to discuss the possibility of enrollment. However, Informed Consent may not be signed until the baby is between 12 and 36 hours of age. 2. Consent may be obtained as soon as possible after 12 hours of age, when the baby enters the well-baby nursery. 3. An infant may be included if the mother has received, or the baby is receiving, antibiotics and the infant is asymptomatic. For example, the baby has no signs of cardiorespiratory distress and is feeding well. Symptomatic infants are excluded (see Exclusions, below). 4. Born at the study hospital site and admitted to the well-baby nursery or admitted to the intensive-care nursery for <12 hours for post delivery observation (delayed transition, temperature or dextrose instability, meconium staining and/or parental concern). 5. All babies on oral feeding with stable cardiorespiratory status and deemed "healthy" upon clinical examination, with normal perfusion as defined by capillary filling of the fingernail. 6. Term neonate (≥38 weeks of completed gestation), OR 7. Near-term neonate (>36<38 weeks of completed gestation; >2,000g birth weight), OR 8. Near-term neonate (>35<38 weeks of completed gestation; >2,500g birth weight) 9. Care provided (primarily) in the well-baby nursery population; 10. Absence of concurrent cardiorespiratory distress, sepsis, major congenital anomalies or need for care in an intensive care nursery; 11. Not participating in another concurrent unrelated study. Exclusion Criteria The study enrolled patients who did not have any of the following exclusion criteria: 1. Any condition that in the opinion of the investigator would make the subject unsuitable for the study. 2. Infants receiving antibiotics who are also symptomatic are excluded. For example, a baby who is feeding poorly or is in cardiorespiratory distress is excluded. 3. Mother has received phenobarbital in past 30 days.



Minimum Age:


Maximum Age:

36 Hours

Healthy Volunteers:


Overall Official
Last Name Role Affiliation
Global Clinical Leader Study Director Mallinckrodt
Facility: Pennsylvania Hospital
Location Countries

United States

Verification Date


Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Active drug-Stannsoporfin

Type: Experimental

Description: Stannsoporfin, single dose 4.5mg/kg administered Intramuscular (parental injection in the thigh) for treatment of jaundice 20 mg/mL 1.5 mL/vial

Label: Reference Therapy-Sham

Type: Sham Comparator

Description: Sham Injection, no injection followed by a Band-Aid to thigh

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Prevention

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News